Head to head
McKesson vs Cencora
Side-by-side on the measures that matter, with a plain-English read. Full detail: MCK · COR
MCK
McKesson
910.33-1.23%
1-year price shape — +22% over the period
Quant Rating C · 65/100
vs
COR
Cencora
317.25+0.28%
1-year price shape — +4% over the period
Quant Rating C · 45/100
1-year performance, rebased to 100
McKesson edges it on the scoreable measures. McKesson has the highest Quant Rating (65); McKesson has done best over the past year (+22%); McKesson earns the most per share.
| MCK | COR | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Distribution | Medical Distribution |
| Last price | 910.33 | 317.25 |
| Change today | -1.23% | +0.28% |
| 1-year return | +21.8% | +3.5% |
| Market cap | $106.14B | $60.54B |
| 52-week range | 722.11 – 996.84 | 243.78 – 375.33 |
| Valuation | ||
| P/E (TTM) | 24.31 | 23.55 |
| P/E percentile, own 5-yr range | 45th | 46th |
| P/B | -25.03 | 19.84 |
| Dividend yield | 0.36% | 0.74% |
| Profitability & growth | ||
| EPS (TTM) | 38.55 | 7.96 |
| Net profit (TTM) | $4.49B | $1.52B |
| Revenue (TTM) | $410.98B | $332.77B |
| Revenue growth (YoY) | +7.7% | +5.1% |
| Gross margin | 3.6% | 4.0% |
| Operating margin | 1.7% | 1.4% |
| Net margin | 1.1% | 0.8% |
| Free cash flow (TTM) | $6.15B | $4.06B |
| Ownership & sentiment | ||
| Institutional ownership | 92.0% | 102.7% |
| Insider activity (12mo) | 23 buy / 25 sell | 30 buy / 18 sell |
| Short interest (% of float) | 2.5% | 2.3% |
| Analyst consensus | 83% buy / 17% hold (12) | 75% buy / 25% hold (12) |
| Analyst price target | $1,001 (+10%) | $373 (+18%) |
| StockVane view | ||
| StockVane Quant Rating | C (65) | C (45) |
| Company | ||
| Employees | 43,000 | 51,000 |
| Founded | 1833 | 1947 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.